首页> 外文期刊>European journal of nuclear medicine >Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pylori breath test.
【24h】

Biokinetics and radiation doses for carbon-14 urea in adults and children undergoing the Helicobacter pylori breath test.

机译:成人和儿童接受幽门螺杆菌呼气试验的碳14尿素的生物动力学和辐射剂量。

获取原文
获取原文并翻译 | 示例
           

摘要

The long-term biokinetics and dosimetry of carbon-14 were studied in nine adults and eight children undergoing carbon-14 urea breath test for Helicobacter pylori (HP) infection. The elimination of 14C via exhaled air and urine was measured with the liquid scintillation counting technique and with accelerator mass spectrometry. After the subjects had been given 110 kBq 14C-urea (children: 55 kBq) orally, samples of exhaled air were taken up to 180 days after administration and samples of urine were collected up to 40 days. Sixteen of the subjects were found to be HP-negative. In these subjects a total of 91.1%+/-3.9% (mean of adults and children +/- standard error of the mean) of the administered 14C activity was recovered. The majority of the administered activity, 88.3%+/-6.2% in adults and 87.7%+/-5.0% in children, was excreted via the urine within 72 h after administration. A smaller fraction was exhaled. In adults 4.6%+/-0.6% of the activity was exhaled within 20 days and in children 2.6%+/-0.3%. Uncertainties in the biokinetic results are mainly due to assumptions concerning endogenous CO2 production and urinary excretion rate and are estimated to be less than 30%. The absorbed dose to various organs and the effective dose were calculated using the ICRP model for urea and CO2. The urinary bladder received the highest absorbed dose: in adults, 0.15+/-0.01 mGy/MBq and in children of various ages (7-14 years), 0.14-0.36 mGy/MBq. The findings indicate that an investigation with 14C-urea gives an effective dose to adults of 2.1+/-0.1 microSv (for 110 kBq) and to children of 0.9-2.5 microSv (for 55 kBq). From a radiation protection point of view, there is thus no reason for restrictions on even repeated screening investigations with 14C-urea in whole families, including children.
机译:在接受碳14尿素呼气试验测试幽门螺杆菌(HP)感染的9名成人和8名儿童中,研究了碳14的长期生物动力学和剂量学。通过液体闪烁计数技术和加速器质谱法测量通过呼出的空气和尿液消除14C。给受试者口服110 kBq 14C-尿素(儿童:55 kBq)后,在给药后180天内采集呼出的空气样本,并在40天内采集尿液的样本。发现其中16名受试者是HP阴性。在这些受试者中,回收的14C活性总计91.1%+ /-3.9%(成人和儿童的平均值+/-平均标准误)。给药后的大部分活动(成年人中为88.3%+ /-6.2%,儿童为87.7%+ /-5.0%)在给药后72小时内通过尿液排泄。呼出一小部分。成人在20天内呼出了4.6%+ /-0.6%的活性,而儿童则为2.6%+ /-0.3%。生物动力学结果的不确定性主要是由于有关内源性CO2产生和尿排泄率的假设,估计小于30%。使用尿素和二氧化碳的ICRP模型计算了对各个器官的吸收剂量和有效剂量。膀胱接受的吸收剂量最高:成人为0.15 +/- 0.01 mGy / MBq,而各个年龄段(7-14岁)的儿童为0.14-0.36 mGy / MBq。研究结果表明,对14C-尿素进行的调查显示,成人有效剂量为2.1 +/- 0.1 microSv(对于110 kBq),儿童有效剂量为0.9-2.5 microSv(对于55 kBq)。从辐射防护的角度来看,甚至没有理由限制甚至在整个家庭,包括儿童中,对14 C-尿素进行反复筛查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号